Cargando…

EE240 Beyond Symptoms Alleviation: Population-Level Benefits of COVID-19 Oral Direct-Acting Antiviral (DAA) Treatment and Resulting Decreases in Infectivity and Transmission

Detalles Bibliográficos
Autores principales:	Chacon-Araya, M., Ortendahl, J.D., Lee, J., Broder, M., Brusky, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256479/ http://dx.doi.org/10.1016/j.jval.2023.03.541

Ejemplares similares

EE333 Assessment of Medically-Attended COVID-19 Patient Risk Profiles and Health Care Resource Utilization (HCRU) and Costs in the U.S.
por: Chacon-Araya, M., et al.
Publicado: (2023)

EE213 Long COVID-19 Associated with 5-Fold Increase in Total Medical Costs and Greater Use of Inpatient and Outpatient Services Compared to Non-Long COVID-19: An Analysis of Real-World Data
por: Chacon-Araya, M., et al.
Publicado: (2023)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

EE240 Estimating the COVID-19 Cost-of-Illness Associated with Comorbidities in a Brazilian Public Hospital
por: Oliveira, LA, et al.
Publicado: (2022)

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
por: Frisk, P., et al.
Publicado: (2018)

Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis
por: Shakeri, Ahmad, et al.
Publicado: (2021)

Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
por: Aebi-Popp, Karoline, et al.
Publicado: (2016)

Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
por: Welzel, Tania M., et al.
Publicado: (2019)

P1096: TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS)
por: Lepkov, Sergey, et al.
Publicado: (2023)

J2EE and beyond
por: Taylor, Art
Publicado: (2003)

Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt
por: Shoun, Aly Atef, et al.
Publicado: (2022)

ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs)
por: Ghanem, Samar, et al.
Publicado: (2023)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series
por: Ambarsari, Cahyani Gita, et al.
Publicado: (2020)

292. No association Between Direct-acting Antiviral (DAA) Therapy and Varicella-Zoster Virus (VSV) Reactivation in an Analysis of 37 Prospective Clinical Trials
por: Rohde, Maximilian, et al.
Publicado: (2019)

Role of Inflammatory/Immune Response and Cytokine Polymorphisms in the Severity of Chronic Hepatitis C (CHC) before and after Direct Acting Antiviral (DAAs) Treatment
por: Ferreira, Joana, et al.
Publicado: (2023)

Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study
por: Pereira, Gustavo H., et al.
Publicado: (2022)

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
por: Brothers, Sarah, et al.
Publicado: (2022)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages
por: Suenaga, Riichiro, et al.
Publicado: (2021)

JBox seam: simplicity and power beyond Java EE
por: Yuan, Michael Juntao, et al.
Publicado: (2007)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
por: Fagiuoli, Stefano, et al.
Publicado: (2023)

S240: TARGETING PRMT1 ALLEVIATES CHRONIC GRAFT-VERSUS-HOST DISEASE BY REDUCING T AND B PATHOGENICITY
por: Zhao, Xiaoyan, et al.
Publicado: (2023)

Benefits of Minimizing the Vertex Detector Material Budget at the FCC-ee
por: Freitag, Leila
Publicado: (2023)

Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection
por: Chuaypen, Natthaya, et al.
Publicado: (2023)

Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals
por: Nguyen, Kelvin, et al.
Publicado: (2017)

Wie 240 elefanten auf kollisionskurs
por: Arzner, Thomas
Publicado: (2007)

Wie 240 Elefanten auf kollisionskurs
por: Arzner, Thomas
Publicado: (2007)

Health Tract, No. 240: Cholera Prevented
Publicado: (1866)

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort
por: d'Arminio Monforte, Antonella, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qq6mkptlfm3n7a64g3qjh3dl1r